The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 5, 2003, Pages 577-584

  Mehta, Shruti H ^a   Moore, Richard D ^a   Thomas, David L ^a   Chaisson, Richard E ^a   Sulkowski, Mark S ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis C; Highly active antiretroviral therapy; HIV; Hyperglycemia; Protease inhibitors

Indexed keywords

EFAVIRENZ; GLUCOSE; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; COMMUNICABLE DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREVALENCE; PRIORITY JOURNAL; RANDOMIZATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BALTIMORE; COHORT STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HOSPITALS, UNIVERSITY; HUMANS; HYPERGLYCEMIA; INCIDENCE; MALE; PREVALENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; URBAN POPULATION;

EID: 0042627763     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200308150-00005     Document Type: Article

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725-1730.
3. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
4. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63-F70.
5. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
6. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
7. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
8. Dube MP, Johnson DL, Currier JS, et al. Protease inhibitor-associated hyperglycaemia. Lancet. 1997;350:713-714.
9. Botella JI, Valero MA, Munoz V, et al. Complete resolution of protease inhibitor induced diabetes mellitus. Clin Endocrinol (Oxf). 2000;52:241-243.
10. Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805-810.
11. Mehta SH, Strathdee SA, Thomas DL. Association between hepatitis C virus infection and diabetes mellitus. Epidemiol Rev. 2001; 23:302-312.
12. Allison ME, Wreghitt T, Palmer CR, et al. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;21:1135-1139.
13. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29: 328-333.
14. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592-599.
15. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-837.
16. Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr Infect Dis Rep. 2001;3:469-476.
17. Moore RD, Stanton D, Gopalan R, et al. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;330:763-768.
18. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52: 1-13,15.
19. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(suppl 1):S5-20.
20. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:245-250.
21. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
22. Currier JS, Boyd F, Kawabata H, et al. Diabetes mellitus in HIV-infected individuals. 9th Conference on Retroviruses and Opportunistic Infections; Seattle, WA; February 24-28, 2002. Abstract.
23. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050-2056.
24. Konrad T, Zeuzem S, Toffolo G, et al. Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection. Digestion. 2000;62:52-59.
25. Behrens GM, Boerner AR, Weber K, et al. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest. 2002; 110: 1319-1327.
26. Petrides AS, DeFronzo RA. Glucose and insulin metabolism in cirrhosis. J Hepatol, 1989;8:107-114.
27. Maserati R, Villani P, Seminari E, et al. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS. 1999;13:870-871.
28. Veronese L, Rautaureau J, Sadler BM, et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother. 2000;44:821-826.
29. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908-914.